Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of International Pharmaceutical Research ; (6): 828-834, 2017.
Artigo em Chinês | WPRIM | ID: wpr-693321

RESUMO

Sodium-glucose co-transportor 2(SGLT2)exerts an important role in the reabsorption of renal glucose,and SGLT2 inhibitors could reduce the blood glucose level in type 2 diabetes mellitus patients by decreasing renal glucose reabsorption and in-creasing urine glucose excretion. This paper briefly reviews the renal regulation of glucose homeostasis and the regulatory mechanism of SGLT2 inhibitors,then summarized the administration,clinical pharmacology,adverse reaction and other aspect of clinical applica-tion of three most representive SGLT2 inhibitors:dapagliflozin,canagliflozin and empagliflozin,in hope of providing reference for clinical use of SGLT2 inhibitors in the future.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA